In Reply We appreciate the letter from Dr Coriat and colleagues in response to our recent report on the combination of hepatic arterial infusion chemotherapy (HAIC) with sorafenib.1 We would like to thank them for their interest in our study. In their letter, they raised 2 issues for discussion: (1) restricting the use of the hepatic arterial infusion strategy to an oxaliplatin-based regimen and to patients with portal vein tumor thrombosis and (2) evaluating HAIC with gemcitabine plus oxaliplatin (GEMOX) with sorafenib.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
He M, Li Q, Shi M. Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma—In Reply. JAMA Oncol. 2019;5(12):1806–1807. doi:10.1001/jamaoncol.2019.4058
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.